Table 3. Stratified analyses: OR and 95% CI for biomarkers of acrylamide exposure and EOC risk in an EPIC nested case-control study in the EPIC cohort.
| Normal and Underweight | Overweight and Obese | Never drinkers | Drinkers | Non-Oral contraceptive users | Oral contraceptive users | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||||||||||
| Cutpoints | Cases | Controls | OR (95%CI)a | Cases | Controls | OR (95%CI)a | Cases | Controls | OR (95%CI)b | Cases | Controls | OR (95%CI)b | Cases | Controls | OR (95%CI)c | Cases | Controls | OR (95%CI)c | |
| HbAA | ≤33.60 | 35 | 37 | 1.00 (ref) | 45 | 67 | 1.00 (ref) | 19 | 26 | 1.00 (ref) | 61 | 78 | 1.00 (ref) | 55 | 74 | 1.00 (ref) | 24 | 30 | 1.00 (ref) |
| 33.61-42.70 | 35 | 42 | 1.01( 0.44-2.33) | 55 | 61 | 1.15( 0.63-2.09) | 27 | 21 | 1.35( 0.51-3.52) | 63 | 82 | 1.11( 0.65-1.92) | 55 | 45 | 1.47( 0.81-2.68) | 32 | 55 | 0.80( 0.34-1.89) | |
| 42.71-54.60 | 28 | 50 | 0.68( 0.29-1.59) | 56 | 55 | 1.52( 0.81-2.87) | 19 | 28 | 0.65( 0.22-1.96) | 65 | 77 | 1.40( 0.80-2.43) | 55 | 58 | 1.22( 0.66-2.26) | 27 | 46 | 1.12( 0.44-2.88) | |
| >54.61 | 39 | 46 | 1.23( 0.54-2.84) | 41 | 59 | 0.93( 0.47-1.82) | 15 | 18 | 0.77( 0.24-2.52) | 65 | 87 | 1.19( 0.67-2.12) | 44 | 62 | 0.85( 0.44-1.66) | 36 | 43 | 1.60( 0.64-4.00) | |
| LRT | 0.07 | 0.42 | 0.18 | ||||||||||||||||
|
| |||||||||||||||||||
| HbGA | ≤25.90 | 35 | 49 | 1.00 (ref) | 27 | 54 | 1.00 (ref) | 11 | 22 | 1.00 (ref) | 51 | 81 | 1.00 (ref) | 44 | 62 | 1.00 (ref) | 16 | 41 | 1.00 (ref) |
| 26.91-35.20 | 38 | 46 | 1.66( 0.76-3.60) | 51 | 59 | 1.45( 0.76-2.78) | 16 | 19 | 1.85( 0.53-6.53) | 73 | 86 | 1.47( 0.87-2.49) | 50 | 57 | 1.22( 0.67-2.24) | 37 | 47 | 2.91( 1.18-7.14) | |
| 35.21-49.90 | 29 | 42 | 1.53( 0.67-3.51) | 72 | 63 | 2.10( 1.08-4.08) | 35 | 26 | 4.32( 1.32-14.18) | 66 | 79 | 1.80( 1.04-3.13) | 67 | 57 | 2.02( 1.09-3.76) | 32 | 47 | 2.33( 0.90-5.99) | |
| >49.91 | 35 | 38 | 1.82( 0.79-4.22) | 47 | 66 | 1.29( 0.64-2.63) | 18 | 26 | 1.39( 0.38-5.03) | 64 | 78 | 1.62( 0.91-2.89) | 48 | 63 | 1.11( 0.57-2.15) | 34 | 39 | 3.33( 1.27-8.77) | |
| LRT | 0.60 | 0.66 | 0.33 | ||||||||||||||||
|
| |||||||||||||||||||
| Sum of HbAA + HbGA | ≤59.80 | 34 | 41 | 1.00 (ref) | 34 | 62 | 1.00 (ref) | 11 | 21 | 1.00 (ref) | 57 | 82 | 1.00 (ref) | 47 | 71 | 1.00 (ref) | 19 | 32 | 1.00 (ref) |
| 59.81-78.70 | 34 | 48 | 1.12( 0.50-2.49) | 62 | 58 | 1.85( 1.00-3.43) | 28 | 22 | 2.80( 0.91-8.59) | 68 | 84 | 1.30( 0.77-2.22) | 57 | 51 | 1.60( 0.88-2.92) | 37 | 54 | 1.59( 0.67-3.80) | |
| 78.80-106.00 | 34 | 45 | 1.27( 0.55-2.93) | 54 | 59 | 1.51( 0.79-2.88) | 26 | 28 | 1.97( 0.59-6.54) | 62 | 76 | 1.52( 0.87-2.63) | 56 | 51 | 1.72( 0.93-3.20) | 30 | 51 | 1.21( 0.48-3.06) | |
| >106.01 | 35 | 41 | 1.48( 0.63-3.50) | 47 | 63 | 1.23( 0.63-2.43) | 15 | 22 | 1.01( 0.27-3.85) | 67 | 82 | 1.46( 0.83-2.58) | 49 | 66 | 1.06( 0.55-2.07) | 33 | 37 | 2.14( 0.83-5.53) | |
| LRT | 0.34 | 0.40 | 0.29 | ||||||||||||||||
|
| |||||||||||||||||||
| Ratio of HbGA/HbAA | ≤0.70 | 39 | 66 | 1.00 (ref) | 28 | 37 | 1.00 (ref) | 3 | 15 | 1.00 (ref) | 64 | 88 | 1.00 (ref) | 39 | 49 | 1.00 (ref) | 26 | 54 | 1.00 (ref) |
| 0.71-0.80 | 39 | 48 | 1.99( 0.96-4.15) | 37 | 55 | 0.88( 0.43-1.78) | 21 | 21 | 15.55( 1.74-138.79) | 55 | 82 | 1.02( 0.61-1.72) | 46 | 59 | 1.02( 0.54-1.91) | 30 | 44 | 2.10( 0.90-4.87) | |
| 0.81-1.00 | 39 | 31 | 3.06( 1.34-7.01) | 65 | 77 | 1.22( 0.62-2.39) | 29 | 24 | 17.90( 2.00-160.05) | 75 | 84 | 1.48( 0.88-2.50) | 69 | 65 | 1.79( 0.96-3.32) | 31 | 41 | 2.21( 0.90-5.45) | |
| >1.01 | 20 | 30 | 1.06( 0.44-2.52) | 67 | 73 | 1.15( 0.59-2.23) | 27 | 33 | 11.20( 1.27-99.05) | 60 | 70 | 1.24( 0.73-2.11) | 55 | 66 | 1.17( 0.63-2.19) | 32 | 35 | 1.86( 0.77-4.51) | |
| LRT | 0.18 | 0.09 | 0.61 | ||||||||||||||||
EOC, epithelial ovarian cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide.
Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, alcohol intake, parity, age at menopause, and age at first menstrual period.
Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, parity, age at menopause, age at first menstrual period, and BMI.
Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, HRT use, alcohol intake, parity, age at menopause, age at first menstrual period, and BMI.
All LRT P-values for effect measure modification are based on the categorical exposure adduct variable.